<DOC>
	<DOCNO>NCT02592421</DOCNO>
	<brief_summary>In Protocol 2 , investigator determine role pancreatic hormone ( increase plasma glucagon decrease plasma insulin concentration ) stimulation EGP follow SGLT2 inhibition .</brief_summary>
	<brief_title>SGLT2 Inhibition Stimulation Endogenous Glucose Production : Protocol 2</brief_title>
	<detailed_description>The inhibition renal ( kidney ) SGLT2 transporter proven effective therapeutic intervention reduce plasma glucose level ( amount glucose find liquid part blood ) HbA1c . In study , investigator hope define role increase plasma glucagon , decline plasma insulin , fall plasma glucose concentration . The investigator examine whether signal increase EGP ( endogenous glucose production ) cause glucosuria ( excess sugar urine , typically associate diabetes ) mediate via decrease plasma glucose insulin concentration , increase plasma glucagon concentration .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>T2DM subject 30 60 yr old BMI = 2535 kg/m2 Must stable dose ( 3 month ) monotherapy combination therapy metformin and/or sulfonylurea HbA1c &lt; 8.0 % Stable body weight ( Â± 3 lb ) precede 3 month Do participate excessively heavy exercise Subjects take drug know affect glucose metabolism ( metformin sulfonylurea ) Individuals evidence proliferative diabetic retinopathy , plasma creatinine &gt; 1.4 female &gt; 1.5 male , 24hour urine albumin excretion &gt; 300 mg</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>